Arabic Arabic English English French French German German
dark

RedHill Biopharma’s Oral Opaganib Significantly Improves Viral Clearance in Phase 2/3 Study in Severely Ill Hospitalized COVID-19 Patients

RedHill Biopharma Ltd. today announced new data from a prespecified analysis of all oral opaganib’s[1] Phase 2/3 study patients with positive PCR at screening, demonstrating that opaganib improved the median time to viral RNA clearance by at least 4 days. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

NeonMind Appoints Canadian Medical Leader in Anesthesiology, Dr. Daniel Bainbridge, MD, FRCPC to Its Specialty Clinics Advisory Board

Next Post

UNIST Partners with Yonsei University Health System to Empower Smart Healthcare

Related Posts
Total
0
Share